The potential of psychedelics to treat a range of mental health conditions continues to attract increasing levels of funding for clinical trials as firms work towards bringing them into mainstream medical use.

Boston-based Preclinical neuroscience company Delix Therapeutics recently closed an initial Series A round of funding, in which it raised $70m for clinical trials of its psychoplastogen compounds.

Read full article
I'm already a subscriber
Author default picture

Lorraine Mullaney

Senior writer
Lorraine is responsible for writing news analysis and assisting with copy-editing. Lorraine is a copywriter and editor who has written and edited words for a wide range of audiences, from local community newspapers to consumer magazines and trade websites.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization